Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla

Abstract

Gd-BOPTA demonstrates the highest longitudinal r1 at all field strengths, which is ascribable to weak protein interaction. The R2/R1 ratio increases at higher field strength only for Gd-BOPTA, hence very short echo times are required for Gd-BOPTA to benefit from the higher longitudinal relaxivity.

Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study)

“…Among the GBCAs currently approved by the FDA, gadobenate dimeglumine (MultiHance; Bracco, Milan, Italy) has proved superior to other GBCAs at equivalent dose for MR imaging of tumors of the CNS. [1][2][3][4][5][6][7][8] The superior diagnostic performance achievable with gadobenate dimeglumine, which is reflected in a recently updated "Summary of Product Characteristics," 9 is due to high in vivo R1 relaxivity (6.3-7.9 L ϫ mmol Ϫ1 ϫ sec Ϫ1 at 1.5T, 10,11 ) which derives from weak and transient interactions of the gadobenate contrast-effective molecule with serum albumin. 12,13 The increased R1 relaxivity leads to increased SI enhancement and thus significantly improved lesion visualization and better depiction of morphologic features relative to those achieved with GBCAs, which do not interact with serum protein, when these agents are administered at an equivalent dose of 0.1 mmol/kg of body weight.…”

Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)

“…Whereas both agents have a linear ionic molecular structure and are widely used for CE-MRA, they differ in that gadobenate dimeglumine possesses markedly higher R1 relaxivity in vivo (6.3-7.9 compared with 3.9 -4.1 L ϫ mmol Ϫ1 ϫ second Ϫ1 at 1.5T 9,10 ). Numerous studies across a range of CE-MRA applications have shown that gadobenate dimeglumine is superior to gadopentetate dimeglumine in terms of diagnostic performance and/or contrast enhancement and image quality when these agents are administered at equivalent doses.…”

Comparison of Gd‐DTPA and Gd‐BOPTA for studying renal perfusion and filtration

“…In this study we compared one of the most widely used gadolinium-containing contrast agents, Gd-DTPA, with the contrast agent Gd-BOPTA. Gd-BOPTA demonstrates a weak and transient binding with serum proteins, thus leading to up to doubled relaxivity under physiological conditions (14). It has proven beneficial for studying liver perfusion and the increased relaxivity improves the image quality of MR angiography, eg, of the renal arteries (16).…”

“…One potentially confounding factor is the interaction of the contrast agent and serum proteins. The contrast agent gadobenate-dimeglumine (Gd-BOPTA) demonstrates weak and transient interactions with serum proteins, causing slowing of the molecular tumbling dynamics, resulting in strong increases in the magnetic relaxivity in solutions containing serum proteins, particularly albumin (13,14). Compared to gadopentetate-dimeglumine (Gd-DTPA), in human plasma relaxivity is increased significantly (14,15), which has proven useful for performing, eg, MR angiography of the renal arteries (16).…”